Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Cookies
Only to see which pages are hard to use, so we can fix them. Nothing is used for ads, and what you type stays hidden (Microsoft Clarity, PostHog). Privacy Policy
Compensation award — excluded from discretionary-purchase analysis.
Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell.
View the official recordSEC Form 4 — Statement of Changes in Beneficial OwnershipAll the details
Dates, kept separate
Transaction date
Sep 14, 2026
Reporting period
Not applicable
Filed with the SEC
Sep 19, 2026
DirectorGrant / award
Context
Classification
grant award
Code A — grant or award
Planned / mechanical clue
Footnote references vesting of compensation awards
Only flagged when a footnote says so; never inferred
Source receipt
Record ID
0001493152-26-043441
Filed / recorded
Sep 19, 2026, 12:17 AM UTC
Added to OQRO
Oct 8, 2026, 2:32 AM UTC
Parser
form4-xml-v2
Data quality
Verified: identifiers matched exactly
Issuer
Vivos Therapeutics, Inc.
Issuer CIK
1716166
Ticker
VVOS
Reporting person
Gregg C Johnson
Relationship
Director
Security
Stock Options (Right to Buy)
Table
Derivative (Table II)
Transaction date
Sep 14, 2026
Transaction code
A
Shares / units
12,000
Price per share
$0.00
Acquired / disposed
Acquired (A)
Shares owned after
12,000
Ownership form
Direct
Amendment
No
Footnotes from the filing
On September 14, 2026 (the "Grant Date"), the Reporting Person received a grant of 12,000 stock options from the Issuer. One-half vested immediately (and the earliest possible exercise date in Table II relates to this tranche), one-fourth will vest on September 30, 2026 and one-fourth will vest on December 31, 2026. The options are exercisable for a period of 10 years from the Grant Date.
Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.
“On the Closing Date, the Company completed the acquisition of (i) 3,057,879 shares of common stock of SOD (the “ SOD Shares ”), representing at least eleven percent (11%) of SOD’s fully diluted capital stock immediately after the Closing (as adjusted, in accordance with Section 1.1 of the Agreement, from the 2,907,338 shares reported in the Prior 8-K), and (ii) the Test Interest, in exchange for the issuance to SOD…”